Salud financiera de hoja de balance de Poseida Therapeutics
Salud financiera controles de criterios 5/6
Poseida Therapeutics tiene un patrimonio de los accionistas total de $60.8M y una deuda total de $58.8M, lo que sitúa su ratio deuda-patrimonio en 96.7%. Sus activos y pasivos totales son $298.7M y $237.9M respectivamente.
Información clave
96.7%
Ratio deuda-patrimonio
US$58.80m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$237.81m |
| Patrimonio | US$60.82m |
| Total pasivo | US$237.87m |
| Activos totales | US$298.69m |
Actualizaciones recientes sobre salud financiera
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Recent updates
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Sep 09Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09FDA lifts clinical hold on Poseida's prostate cancer cell therapy study
Nov 02Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($254.3M) de PSTX superan a sus pasivos a corto plazo ($102.4M).
Pasivo a largo plazo: Los activos a corto plazo de PSTX ($254.3M) superan a sus pasivos a largo plazo ($135.4M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: PSTX tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de PSTX ha crecido de 71.7% a 96.7% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: Aunque no es rentable PSTX tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.
Pronóstico de cash runway: PSTX no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 7.4% al año.